Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Mesothelin-Targeted Antibody Drug Conjugate

Geo Regions

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666 (SGN-MesoC2) is an investigational compound. Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

  • Mesothelin (MSLN) is a 40-kDa cell surface differentiation antigen present on normal mesothelial cells and plays a role in the regulation of cell proliferation, growth, and adhesion signaling1
  • Overexpression of mesothelin has been identified in many different tumor types (including lung and ovarian cancers) and in hematological malignancies such as acute myeloid leukemia2
  • It’s limited expression in normal tissues and overexpression in tumor tissues can result in reduced nonspecific toxicity, making MSLN an attractive target for oncology drug development3

 

  • PF-08052666 (SGN-MesoC2) is an ADC that targets human mesothelin4
  • PF-08052666 (SGN-MesoC2) consists of an anti-MSLN mAb conjugated to SGD-12280 (a novel topoisomerase 1 inhibitor) by a cleavable methylsulfonylpyrimidine tripeptide linker4

Stage of Development

Other
Advanced/Metastatic Solid Tumors
Phase 1 Monotherapy and Combination
This information is current as of October 30th 2024.

ADC, antibody-drug conjugate; mAb, monoclonal antibody; MesoC2: mesothelin campothecin 2.

REFERENCES:  1. Hassan et al. Clin Cancer Res. 15 June 2004; 10 (12): 3937–3942; 2. Faust et al. Cancers 2022, 14, 1550; 3. Celbi C. Mol. Ther. Oncology. 31,100756, 2023; 4. Data on File. INVESTIGATOR’S BROCHURE. SGN-MesoC 2. Number: 02. 11-Mar-2024; 5.  Clinicaltrials.gov.  https://clinicaltrials.gov/study/NCT06466187.  Access October 22, 2024